Parkinson disease (PD) is a prevalent neurodegenerative disorder worldwide, yet no treatment prevents or cures PD, and many symptoms, including pain, remain undertreated. Pain is common and debilitating in PD, with limited relief from dopaminergic treatments, suggesting the involvement of non-dopaminergic neurotransmission systems. In individuals with monogenic PD carrying a PTEN-induced putative kinase 1 (PINK1) mutation, abnormal sensorimotor profiles and pain manifestation have been observed, underscoring the need for preclinical models to investigate these mechanisms.